The Patent Finder
CE

Celcuity Inc.

First filing 2012
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Nine patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Jun 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2032
Next term end
5
Patent families

When these terms end

Each bar runs from grant to computed term end. 2016 to 2042.
US 9,404,915 Whole Cell Assays and Methods Jun 12, 2032
US 11,073,509 Assays and Methods for Determining the Responsiveness of an Individual Subject to a Therapeutic Agent Jun 12, 2032
US 10,041,934 Whole Cell Assays and Methods Jun 12, 2032
US 10,976,307 Whole Cell Assays and Methods Jun 12, 2032
US 12,215,356 Methods of Preparing a Primary Cell Sample no later than Jan 7, 2037
US 11,591,573 Methods of Preparing a Primary Cell Sample Jul 28, 2038
US 12,320,799 Methods of Measuring Signaling Pathway Activity for Selection of Therapeutic Agents no later than Jan 21, 2039
US 11,333,659 Methods of Measuring Signaling Pathway Activity for Selection of Therapeutic Agents Dec 29, 2039
US 12,350,276 Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA Aug 31, 2042
202120262031203620412042
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
4 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Whole Cell Assays and Methods US 9,404,915
The most cited patent in this portfolio, cited by 30 later US patents, top 25% of utility patents granted in 2016 in our data. Protection runs to 2032.
Ends Jun 2032 · High confidence Also notable
Methods of Measuring Signaling Pathway Activity for Selection of Therapeutic Agents US 11,333,659
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2039.
Ends Dec 2039 · High confidence Also notable
Methods of Preparing a Primary Cell Sample US 11,591,573
The newest of the three, granted 2023. It anchors the portfolio to 2038, later than anything else here.
Ends Jul 2038 · Medium confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Whole Cell Assays and Methods3 in forceto Jun 2032
Methods of Measuring Signaling Pathway Activity for Selection of Therapeutic Agents2 in forceto Dec 2039
Methods of Preparing a Primary Cell Sample2 in forceto Jul 2038
Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA1 in forceto Aug 2042
Assays and Methods for Determining the Responsiveness of an Individual Subject to a Therapeutic Agent1 in forceto Jun 2032

Patents held now

Soonest term end first.

Showing 1 to 9 of 9

PatentTitleStatusExpiresConfidence
US 9,404,915Whole Cell Assays and Methods
In force
 · High confidence
In forceHigh confidence
US 10,041,934Whole Cell Assays and Methods
In force
 · High confidence
In forceHigh confidence
US 10,976,307Whole Cell Assays and Methods
In force
 · High confidence
In forceHigh confidence
US 11,073,509Assays and Methods for Determining the Responsiveness of an Individual Subject to a Therapeutic Agent
In force
 · Medium confidence
In forceMedium confidence
US 12,215,356Methods of Preparing a Primary Cell Sample
In force
 · Low confidence
In forceLow confidence
US 11,591,573Methods of Preparing a Primary Cell Sample
In force
 · Medium confidence
In forceMedium confidence
US 12,320,799Methods of Measuring Signaling Pathway Activity for Selection of Therapeutic Agents
In force
 · Medium confidence
In forceMedium confidence
US 11,333,659Methods of Measuring Signaling Pathway Activity for Selection of Therapeutic Agents
In force
 · High confidence
In forceHigh confidence
US 12,350,276Methods for the Treatment of Cancer Using 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-Dimorpholin-4-YL-1,3,5-Triazin-2-YL)PHENYL]UREA
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 9: 4 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
Export every term end as CSV · Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited